Investors

We have strong financial and industrial shareholders.

Annual financial statements, quarterly reports and presentations.

Please contact our IR Contacts for any queries.

With support from Bristol-Myers Squibb and Ultimovacs, UV1 will be tested in a large, randomized combination trial in mesothelioma initiated by Oslo University Hospital.